Us Stem Cell Stock Performance
| USRM Stock | USD 0.0001 0.00 0.00% |
The entity owns a Beta (Systematic Risk) of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and US Stem are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days US Stem Cell has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, US Stem is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
USRM |
US Stem Relative Risk vs. Return Landscape
If you would invest 0.01 in US Stem Cell on October 3, 2025 and sell it today you would earn a total of 0.00 from holding US Stem Cell or generate 0.0% return on investment over 90 days. US Stem Cell is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than USRM, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
US Stem Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for US Stem's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as US Stem Cell, and traders can use it to determine the average amount a US Stem's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| USRM |
Based on monthly moving average US Stem is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of US Stem by adding US Stem to a well-diversified portfolio.
US Stem Fundamentals Growth
USRM Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of US Stem, and US Stem fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on USRM Pink Sheet performance.
| Return On Asset | -8.45 | |||
| Operating Margin | (19.95) % | |||
| Current Valuation | 12.15 M | |||
| Shares Outstanding | 634.4 M | |||
| Price To Earning | (1.12) X | |||
| Price To Sales | 30.36 X | |||
| Revenue | 3.07 M | |||
| EBITDA | (2.61 M) | |||
| Cash And Equivalents | 10.33 K | |||
| Total Debt | 722.06 K | |||
| Debt To Equity | (1.03) % | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (1.21 M) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 89.84 K | |||
| Retained Earnings | (122.08 M) | |||
| Current Asset | 320 K | |||
| Current Liabilities | 6.96 M | |||
About US Stem Performance
By examining US Stem's fundamental ratios, stakeholders can obtain critical insights into US Stem's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that US Stem is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida. US Stem operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about US Stem Cell performance evaluation
Checking the ongoing alerts about US Stem for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for US Stem Cell help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| US Stem Cell generated a negative expected return over the last 90 days | |
| US Stem Cell has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 3.07 M. Net Loss for the year was (3.84 M) with profit before overhead, payroll, taxes, and interest of 148.72 K. | |
| US Stem Cell currently holds about 10.33 K in cash with (1.21 M) of positive cash flow from operations. |
- Analyzing US Stem's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether US Stem's stock is overvalued or undervalued compared to its peers.
- Examining US Stem's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating US Stem's management team can have a significant impact on its success or failure. Reviewing the track record and experience of US Stem's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of US Stem's pink sheet. These opinions can provide insight into US Stem's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in USRM Pink Sheet
US Stem financial ratios help investors to determine whether USRM Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in USRM with respect to the benefits of owning US Stem security.